SCREENING AND PREVENTIVE TREATMENT OF LATENT TUBERCULOSIS INFECTION IN PREGNANT WOMEN: DIAGNOSTIC ACCURACY, CLINICAL EFFICACY, AND SAFETY ALGORITHMS
Keywords:
Latent tuberculosis infection, Pregnancy, Antenatal screening, QuantiFERON-TB Gold Plus, Isoniazid preventive therapy, Pyridoxine, Scopus.Abstract
Background: Pregnant women represent a high-risk group for the reactivation of latent tuberculosis infection (LTBI) due to physiological immunomodulation during gestation. Unmanaged LTBI progression to active tuberculosis leads to adverse maternal and neonatal outcomes. This study evaluated the comparative diagnostic accuracy of Interferon-Gamma Release Assays (IGRA / QuantiFERON-TB Gold Plus) versus Tuberculin Skin Test (TST), treatment completion rates, and safety profiles of tuberculosis preventive treatment (TPT) in pregnant women.
References
1. World Health Organization. (2024). WHO consolidated guidelines on tuberculosis: Module 1: Prevention - Tuberculosis preventive treatment. Geneva: World Health Organization.
2. Gupta, A., Montepiedra, G., Aaron, L., Theron, G., McCarthy, K., Bradford, S., ... & IMPAACT P1078 TB APPRISE Study Group. (2019). Isoniazid preventive therapy in HIV-infected pregnant and postpartum women. New England Journal of Medicine, 381(14), 1333-1346. DOI: 10.1056/NEJMoa1813060.
3. Centers for Disease Control and Prevention. (2024). Tuberculosis Clinical Care and Treatment During Pregnancy. CDC TB Guidelines, Atlanta, GA.
4. Hirsch-Moverman, Y., Hsu, A., Abrams, E. J., Killam, W. P., Moore, B., & Howard, A. A. (2024). Guidelines for tuberculosis screening and preventive treatment among pregnant and breastfeeding women living with HIV. PLOS ONE, 19(4), e0296993.
5. Winters, N., Belknap, R., Benedetti, A., et al. (2023). Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. The Lancet Respiratory Medicine, 11(9), 782-790.
6. Shah, M., Dorman, S. E., & Solomon, C. G. (2021). Latent Tuberculosis Infection. New England Journal of Medicine, 385(24), 2271-2280.
7. Mathad, J. S., & Gupta, A. (2012). Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. Clinical Infectious Diseases, 55(11), 1532-1549.
8. Menzies, D., Adjobimey, M., Ruslami, R., et al. (2018). Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. New England Journal of Medicine, 379(5), 440-453.
